Patient advocacy groups are excited for Medicare’s upcoming listening sessions that will offer patients a chance to provide the Center for Medicare and Medicaid Services insight into the first slate of drugs subject to US government price negotiations while acknowledging that this initial foray into patient engagement with CMS is not ideal and that they are looking for ways to improve the process in the future.
As Medicare Drug Negotiation Patient Sessions Kick Off, Advocates Already Eyeing Improvements
Patient advocates see IRA patient listening sessions as an opening to push CMS to have more conversations on access issues in general, but first they want to work on improving the current process.
